Portugal: Riding the Wave of Economic Reform - Pharmaceutical Executive

ADVERTISEMENT

Portugal: Riding the Wave of Economic Reform


Pharmaceutical Executive


Make no mistake - despite what many regard as good prospects for the coming years, general managers of multinationals doing business in Portugal are very concerned. Over the 10 years prior to the beginning of 2006, inflation in Portugal climbed 35% and the prices of pharmaceuticals grew by only 7%. Drug prices have been frozen since 2002, and the industry has experienced two consecutive 6% price decreases since September 2005. In addition to that, the Portuguese pharmaceutical market is a very competitive one. Among the country's roughly 200 players, the market leader, MSD, holds a market share of 6.4%.


MSD's building in Portugal: MSD Portugal consolidated its market leading position in 2006
According to data provided by the consulting firm IMS Health Iberia, the Portuguese market struggled to reach a 4.7% sales increase during 2006. This growth was largely driven by the evolution of generics (which reached a 16% market penetration by the beginning of 2007), the boost in OTC products since they were cleared for sale in non-pharmacy outlets, and new products brought to the market.

The good news is that, according to the IMS Health prognosis, the next four years should be better than the last two. The Portuguese pharmaceutical industry should expect a growth rate of approximately 6% in the retail business and 9% in the hospital business until 2010 - that is, unless the government decides to follow the path of further price reductions.

This sponsored supplement was produced by Focus Reports.
Project Publisher : Jessica Santos
Project Editor : Thiago Fontoura Struminski
Editorial Contributor : Alexa Arce
Art Director : Marie Chevallier
For exclusive interviews and more info please log on http://www.focusreports.net/ or contact us at

So, Why Invest in Portugal?


Gilda Parreira
Ironically one of Portugal's major weaknesses is also one of its major attractions. The country's pharmaceutical purchases represent a large proportion of its public health expenditure – around 28%, which is among the highest in Europe. It is, in fact, as Minister of Health Antonio Correia de Campos points out, "a world reference. Spreading the figures," he says, " 1.5 billion (US$2 billion) is spent on ambulatory care plus 0.8 billion (US$1 billion) in hospitals." The 2.3 billion (US$3 billion) spent on pharmaceuticals out of 8.7 billion (US$ 11.5 billion) "is a considerable amount," he concludes.

A Competitive Advantage for Portuguese Producers

Antonio Barros Ferreira, executive director of the 100% Portuguese company Lusomedicamenta, has a positive perspective on the local pharmaceutical players. "The fear often channeled by the companies operating in Portugal is related to the future of the Portuguese market, not the Portuguese industry," he says. "Obviously, we are also affected by these constraints in the Portuguese market, but not on the same scale. I believe that, although it is a difficult process, more and more Portuguese companies will shift their capabilities to exports, and that will guarantee the sustainability of the Portuguese pharmaceutical industry."


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here